How should waxing and waning axillary lymphadenopathy be evaluated and managed?

Evaluation and Management of Waxing and Waning Axillary Lymphadenopathy

Begin with axillary ultrasound as the cornerstone initial test to assess node morphology, followed by diagnostic mammography or digital breast tomosynthesis to exclude an occult breast primary. 1

Understanding the Clinical Context

Waxing and waning axillary lymphadenopathy most commonly reflects benign reactive processes—infectious, inflammatory, or autoimmune conditions—but systematic evaluation is mandatory because lymphoma can present with fluctuating nodes. 2 The fluctuating nature does not exclude malignancy. Metastatic breast cancer accounts for approximately 26% of axillary lymphadenopathy cases, though fewer than 1% of breast cancers initially present solely as isolated axillary adenopathy. 2

Initial Imaging Strategy

First-Line Imaging

• Axillary ultrasound is the primary imaging modality because it distinguishes solid from cystic lesions and evaluates critical morphologic features: cortical thickness, hilum integrity, node shape (oval versus rounded), and vascularity on Doppler. 1, 2
• Diagnostic mammography or digital breast tomosynthesis should be performed concurrently to detect any occult breast primary malignancy. 1
• Do not use FDG-PET/CT as the initial imaging test for isolated axillary masses of unknown cause; it provides no diagnostic advantage over ultrasound. 1, 2

Bilateral Versus Unilateral Presentation

• Bilateral axillary lymphadenopathy suggests systemic disease—lymphoma, leukemia, autoimmune disorders—and only rarely indicates bilateral breast cancer. 1, 2
• Unilateral lymphadenopathy requires focused evaluation for breast cancer, regional infection, or localized inflammatory processes. 1

Sonographic Criteria for Biopsy Versus Observation

Proceed to Ultrasound-Guided Core Biopsy When:

• Complete loss of the central fatty hilum 1
• Rounded rather than oval node shape 1
• Increased vascularity on Doppler imaging 1
• Persistent or progressive enlargement on follow-up imaging 3

Observation Is Appropriate When:

• Preserved fatty hilum is present 1
• Node morphology is benign (oval shape, normal cortical thickness) 1
• Clinical history provides a reasonable benign explanation (e.g., recent infection, dermatologic condition) 4

Special Consideration: COVID-19 Vaccination-Related Adenopathy

The high immunogenicity of mRNA COVID-19 vaccines causes axillary lymphadenopathy in 0.3–53% of recipients, with an average duration exceeding 100 days. 3 This presents a diagnostic challenge in differentiating vaccine-related reactive nodes from malignant causes.

Risk-Stratified Management Approach

Low-Risk Patients (no cancer history, adenopathy ipsilateral to recent COVID-19 vaccine given ≤3 months ago):

• May be managed expectantly without routine follow-up imaging 1
• If lymphadenopathy persists beyond 3 months after vaccination, perform sonographic follow-up after an additional 3 months 3
• Biopsy is recommended if nodes remain abnormal, are progressive, or demonstrate suspicious morphology on control sonography 3

High-Risk Patients (known breast cancer, head/neck cancer, melanoma, or lymphoma):

• Proceed directly to tissue biopsy regardless of vaccination timing 1
• Do not delay cancer staging or treatment to await resolution of possible vaccine-related adenopathy 1, 3
• Suspicious lymph nodes should be clarified before starting oncological therapy, irrespective of vaccination status, according to guidelines and without delaying therapy 3

Practical Vaccination Documentation

• Document vaccination dates, laterality of administration, and vaccine type on all breast imaging intake forms 5, 6
• Schedule screening mammography before vaccination or ≥4–6 weeks after the final vaccine dose to reduce false-positive findings 1
• Administer all vaccine doses contralateral to the site of primary malignancy whenever applicable 5

When Mammography Is Negative but Nodes Remain Suspicious

Breast MRI is recommended when diagnostic mammography or digital breast tomosynthesis is negative for a primary breast malignancy in a patient with suspicious axillary lymphadenopathy; MRI detects occult breast cancer in more than two-thirds of such patients. 4, 1 MRI also characterizes axillary masses by determining involvement of adjacent vessels, chest wall, and other axillary structures. 4

Management Algorithm for Waxing and Waning Nodes

1. Obtain detailed history: vaccination dates and laterality, recent infections, autoimmune conditions, dermatologic issues, known malignancies 3, 5

2. Perform axillary ultrasound + diagnostic mammography/DBT 1, 2

3. Assess sonographic morphology:

   • Benign features (preserved hilum, oval shape) → observation or short-interval follow-up if clinically appropriate 1
   • Suspicious features (loss of hilum, rounded shape, increased vascularity) → proceed to step 4 1

4. Risk stratify:

   • Low-risk + recent ipsilateral COVID-19 vaccine (<3 months) → follow-up ultrasound 3 months after second vaccine dose 1, 3
   • High-risk or no vaccine history → ultrasound-guided core biopsy with marker-clip placement 1, 3

5. If mammography negative and nodes remain suspicious → breast MRI 4, 1

6. If nodes persist or progress at follow-up → biopsy regardless of vaccination status 3

Common Pitfalls to Avoid

• Do not assume all waxing and waning lymphadenopathy is benign; lymphoma can present with fluctuating nodes. 2
• Do not delay biopsy in patients with known or suspected malignancy to await resolution of possible vaccine-related adenopathy. 1, 3
• Do not perform routine axillary lymph node dissection in clinically node-negative breast cancer; sentinel lymph node biopsy offers equivalent survival with reduced morbidity. 1
• Do not use advanced imaging (CT, PET/CT) as the initial modality for isolated axillary masses. 1, 2
• Do not omit excision biopsy follow-up when fine-needle aspiration cytology shows benign reactive changes but clinical suspicion remains high; however, in the majority of cases with benign reactive cytology and negative culture, excision biopsy does not alter management. 7

Tissue Sampling Technique

When biopsy is indicated, perform ultrasound-guided core-needle biopsy rather than fine-needle aspiration, as core biopsy provides architectural information critical for distinguishing reactive hyperplasia from lymphoma. 1 Place a marker clip in any biopsy-proven positive node before neoadjuvant chemotherapy to enable targeted axillary dissection. 1